ADS032: A Novel Dual NLRP1 & NLRP3 Inhibitor to Target Inflammasome Inflammation

Time: 11:30 am
day: Day 2 - Track B - Morning


  • Learn about ADS032, a novel dual inflammasome inhibitor
  • Discover how ADS032 reduces inflammation both in vitro and in vivo
  • Evaluate how ADS032 reduces the inflammatory burden during inflammasome-related disease